The Role of the Windsor Framework in Northern Ireland: Redefining Medicine Supply in a Divided Market
Published in Social Sciences, Pharmacy & Pharmacology, and Economics

Our journey began with a curiosity about how medicines reach patients, particularly in areas with complex political and regulatory environments. Northern Ireland(NI) is one such region that faced major challenges in the supply of medicine following Brexit. Though NI was part of the United Kingdom (UK), it shared a border with the Republic of Ireland, a European Union member state. Because of this situation, NI had to navigate a dual regulatory system. This meant that a single medicinal product had to comply with both MHRA (UK) and EMA (EU) requirements, which created confusion after Brexit, especially in how medicines were approved, labelled, and supplied to NI.
The Windsor Framework was announced in February 2023 to address these challenges and came into effect from 01 January 2025. This new agreement between the UK and EU aims to provide regulatory clarity and smoother access to medicines throughout the UK, including Northern Ireland.
Our recently published paper in Therapeutic Innovation & Regulatory Science (https://doi.org/10.1007/s43441-025-00753-7) provides a comparative analysis of how medicine regulations in NI have changed before and after the implementation of the Windsor Framework, focusing on areas such as licensing, QP batch release, labelling, supply routes, advertising and pharmacovigilance reporting. This review is a practical guide for stakeholders such as manufacturers, Marketing Authorisation Holders and regulatory professionals to understand the regulatory changes and their practical implications.
Need for the Windsor Framework:
- To avoid a hard border between NI and the Republic of Ireland while maintaining the integrity of the EU single market.
- To resolve dual regulatory conflicts where medicines in NI had to meet the MHRA (UK) and EMA (EU) regulations, leading to delayed approvals of new medicines and duplication of existing data.
- To address medicine shortages caused by disrupted supply chains and complex import requirements post-Brexit.
- To simplify licensing and labelling processes and reduce the administrative burden on pharmaceutical manufacturers and wholesalers operating across the UK and EU markets.
- To restore patient access and public confidence by ensuring a faster and more reliable supply of medicines throughout the UK, including NI (1)
Impact of the Windsor Framework:
The key improvements of the Windsor Framework include:
- MHRA becomes the sole authority: MHRA is now the sole regulatory authority for approving medicines across the UK (including NI). There is no longer a need to comply with overlapping EU regulations.
- Unified Licensing and Labelling: A medicinal product no longer requires two marketing authorisations (one from the MHRA and one from the EMA). Instead, a UK-wide license can be mandatorily used with a ‘UK Only’ statement on outer packs.
- Falsified Medicines Directive (FMD) features are no longer mandatory: The EU FMD, which required barcodes and other serialisation features, has been disapplied in NI and has to meet UK safety requirements.
- Simplified Customs: Green & Red Lanes: A green lane has been introduced for products moving within the UK, i.e., between Great Britain and Northern Ireland or vice versa, which are subjected to fewer checks. The red lane system is for products moving between the EU and UK (including NI) subject to stricter checks.
- Pharmacovigilance: Pharmacovigilance and safety reporting are now fully monitored by the UK’s MHRA system(2).
The Future of the Windsor Framework:
The Windsor Framework was not only introduced to streamline the process of movement of goods across NI–GB–EU, but it was also intended to reduce the political stress induced due to Brexit. The shared island of Ireland has been in a chaotic environment since 2020. However, the NI/Ireland protocol was introduced to avoid a hard border between the two countries; the failure to completely implement the protocol increased both countries' political and cultural tensions. Hence, the Windsor Framework is expected to foster a more united and peaceful relationship among the UK, NI and the EU. Looking ahead, the framework may shape NI’s role in different ways. Some foresee the possibility of a united Ireland, while others warn of the NI area becoming politically isolated if the internal tensions in the UK grow further. Alternatively, NI may continue to hold a special status, benefiting from links to the UK and EU. Though challenges remain, the framework offers a chance to build stability and a foundation for cooperation in a complex post-Brexit landscape(3).
References:
- Northern Ireland Protocol: The Windsor Framework - House of Commons Library [Internet]. [cited 2025 Apr 14]. Available from: https://commonslibrary.parliament.uk/research-briefings/cbp-9736/
- The Windsor Framework - further detail and publications - GOV.UK [Internet]. [cited 2025 Apr 14]. Available from: https://www.gov.uk/government/collections/the-windsor-framework-further-detail-and-publications
- Diamond P, Colfer B. THE WINDSOR FRAMEWORK AND ITS IMPLICATIONS. 2024 [cited 2025 Apr 15]; Available from: www.triptyque.be
Follow the Topic
-
Therapeutic Innovation & Regulatory Science
This is a peer-reviewed journal that focuses on medical product discovery, development, regulation, access, and policy.
Related Collections
With collections, you can get published faster and increase your visibility.
Recent Advances in Oncology Clinical Trials
Advancements in cancer research, fueled by scientific breakthroughs and innovative therapies, continue to reshape oncology drug development. Novel statistical methods play a crucial role in this progress, and the DahShu Innovative Design Scientific Working Group (IDSWG) Oncology Team has been at the forefront of promoting and applying these cutting-edge approaches.
To further this mission, we are curating a special collection, encouraging multidisciplinary experts in oncology clinical development to contribute with original research articles, reviews, and case studies exploring the following topics: 1) Innovative and adaptive trial designs; 2) Applications of artificial intelligence in oncology trial design and execution; 3) Integration of real-world or external data to inform go/no-go and regulatory decision-making; 4) Master protocols to accelerate clinical development and dose optimization strategies; 5) Special considerations in trial design for novel cancer agents.
While submissions are open to all, we kindly ask prospective authors to reach out to the guest editors—Freda Cooner, Philip He, and Munish Mehra—to discuss their ideas before submission.
When submitting a manuscript, please tag your submission as part of the "Oncology Clinical Trials" collection when prompted. We look forward to your contributions in shaping the future of oncology clinical research!
Publishing Model: Hybrid
Deadline: Nov 01, 2025
Patient Preferences to Inform Decision Making in Medical Product Development
Therapeutic Innovation and Regulatory Science (TIRS) is calling for papers for a special collection entitled Patient Preferences to Inform Decision Making in Medical Product Development.
The number of patient preference studies related to treatment choice has increased substantially in recent years. Many of these studies focus on eliciting patients’ preferences for attributes of treatments that have recently received or soon will be considered for marketing authorization by regulators. Applications of preference methods to the myriad decisions that sponsors encounter earlier in clinical development have been fewer in number.
This special collection will focus on applications of patient preference methods to elicit patient input to inform clinical development decisions. Such decisions include, but are not limited to: endpoint identification and selection, clinical trial design, clinically meaningful changes in outcomes, target product profiles, and weighting for composite endpoints and preference-weighted PROs.
Papers will be considered if they address explicitly decisions that sponsors, regulators, and other decision makers need to make prior to an application for market authorization. Although theoretical and methods papers will be considered, preference will be given to empirical applications.
For questions regarding suitable content, submission status, and guidelines, please email Dr. Sandra Blumenrath, Managing Editor of TIRS, at Sandra.Blumenrath@diaglobal.org.
Publishing Model: Hybrid
Deadline: Ongoing
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in